Close menu




June 2nd, 2021 | 08:59 CEST

Aspermont, Commerzbank, SGL Carbon - Potential after renewal

  • Investments
Photo credits: pixabay.com

Sometimes it is a gradual process, but sometimes it is a sudden event like the Corona pandemic. A company gets into trouble and the management has to develop strategies that will nevertheless lead the business into the future. But increasing efficiency and making quick decisions alone will not help. Ideally, business models should be checked for resilience early enough and not just when the tree is on fire. A realignment also always offers an opportunity. Today, we have taken a look at three stocks that are still in a state of upheaval but offer definite potential for your portfolio.

time to read: 3 minutes | Author: Armin Schulz
ISIN: AU000000ASP3 , DE000CBK1001 , DE0007235301

Table of contents:


    Aspermont - Turnaround already achieved

    Aspermont is a media publisher focused on the global resources industry. Some of its brands, such as Mining Journal, have a 185-year history. However, the time of print media is slowly but surely running out. Management recognized the problems very early on and has been busy restructuring for some time. The goal is to become a digital media company, and the Australians are on a very good path.

    Aspermont has been dabbling in paywall offerings since 2000 and has 4 million active users in its largest business area, mining. In addition, a solution for B2B media is to be developed, which is already in the pilot phase and is based on over 7 million customer contacts. As a result, there are three business units, Anything as a Service (XaaS), Data and Service. XaaS provides customers with content. Data is used to analyze customer behavior and can generate corresponding B2B leads. The services provide B2B customers with the ability to receive end-to-end marketing solutions.

    When local commodity trade shows were canceled due to the Corona pandemic, the Company turned to the Virtual Event & Exhibition solution already in development. The result was a 365-day virtual trade show where regular updates appear and leads are generated for Aspermont's customers. The successful work can be seen from the net cash position, which increased by USD 7.1 million in 2020, deducting USD 3 million from a placement. The transformation seems successful and there are excellent growth prospects.

    Commerzbank - If the interest rates rise, one should be a COBA shareholder

    Commerzbank has been in crisis since the Lehman bankruptcy and was ultimately rescued by the German government. Since then, the bank has been in reorganization mode and is trying to reposition itself. It has joined the United Nations Net-Zero Banking Alliance and aims to become climate-neutral within Commerzbank by 2040. By 2050, the entire loan and investment portfolio is to neutralize CO2 emissions entirely. The stated goal is to actively drive the transformation to a sustainable economy.

    Technically, Commerzbank wants to be present in the upcoming blockchain market and is in the process of developing digital marketplaces with Deutsche Börse and Fintech 360X. On these platforms, investors will be able to invest in illiquid assets such as art objects or real estate using tokens. Another alliance was concluded with Evonik and BASF, with which a cloud-based blockchain platform is being tested to process payment transactions automatically.

    The figures for the first quarter were decent, but at the same time, the job cuts continue. The big question is: Are interest rates rising again? Due to Commerzbank's large lending business, a 1% increase in interest rates would improve EUR 600 million in net interest income. Bond rates have been rising in the US since the beginning of the year. Blackrock reported a holding of over 5% on May 28. That, too, is a sign that the bank has potential.

    SGL Carbon - In the midst of restructuring

    SGL Carbon, one of the world's largest producers of carbon and graphite, is still in the early stages of restructuring. The loss of 2019 was exceeded again in 2020, also due to Corona. The result was a loss of EUR 132 million. Management reacted in the same year with job cuts and cost-cutting measures. Parts of the loss in 2020, therefore, also resulted from this.

    After the first quarter, the Company had already cut 200 of its 500 jobs. In addition, there are to be recurring savings in material costs of over EUR 100 million. This program is to be implemented by the end of 2022. The Company puts the cost of this at around EUR 40 million. For 2021, the Company hopes for a slight increase in sales and expects a significantly lower loss.

    The share has left its downward trend, but the transformation of the Company is far from complete. With the end of the Corona pandemic, sales could rise again, making the group profitable again in the long term. The next exciting date for investors will be August 12, when the Company plans to present new financial figures.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read